Condition: Intrahepatic Cholangiocarcinoma · Sponsor: Fujian Provincial Hospital
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
This description comes directly from the study's public registry record.
Maolin Yan, Doctor · 15960066307 · yanmaolin74@163.com
Junyi Wu, Doctor · 15059162797 · 1248087863@qq.com
Always discuss trial participation with your own doctor first.
| Fujian Provincial Hospital | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06643208